

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Kerstin MENANDER
Robert SOBOL

Serial No.: 10/598,356

Filed: August 24, 2006


For: TREATMENT OF RECURRENT
CANCER WITH P53 AND RADIO-AND
CHEMOTHERAPIES

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: INGN:120US

Confirmation No.: 2981

CERTIFICATE OF ELECTRONIC TRANSMISSION 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:	
February 23, 2007 Date	 Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INGN:120US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 23, 2007

Form PTO-1449 (modified)		Atty. Docket No.: INGN:120US	Serial No.: 10/598,356
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Kerstin MENANDER Robert SOBOL	
		Filing Date: August 24, 2006	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0077313	6/20/02	Clayman	514	44	10/1/01
	A2	2002/0006914	1/17/02	Sobol et al.	514	44	1/26/01
	A3	5,747,469	5/5/98	Roth et al.	514	44	4/25/94
	A4	6,017,524	1/25/00	Roth et al.	424	93.2	10/13/92
	A5	6,143,290	11/7/00	Zhang et al.	424	93.2	4/7/94
	A6	6,410,010	6/25/02	Zhang et al.	424	93.2	10/29/93
	A7	6,511,847	1/28/03	Zhang et al.	435	320.1	9/21/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Alexander <i>et al.</i> , "Tumor-targeted sensitization to chemotherapy by systemically delivered ligand mediated wtp53 gene therapy," <i>Proc. Am. Assoc. Can. Res. Ann. Meet.</i> , 40:596, 1999.
	C2	Browman and Cronin, "Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials," <i>Semin. Oncol.</i> , 21:311-319, 1994.
	C3	Buller <i>et al.</i> , "Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500," <i>Cancer Gene Therapy</i> , 9:567-572, 2000.
	C4	Chang <i>et al.</i> , "Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy," <i>Archives of Otolaryngology Head and Neck Surgery</i> , 123(5):507-512, 1997.
	C5	Clayman <i>et al.</i> , "Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma," <i>J. Clin. Oncol.</i> , 16(6):2221-2232, 1998.

25747324.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Affy. Docket No.: INGN:120US	Serial No.: 10/598,356
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Kerstin MENANDER Robert SOBOL	
		Filing Date: August 24, 2006	Group: Unknown
		U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C6	Gurnani <i>et al.</i> , "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer," <i>Cancer Chemother. Pharmacol.</i> , 44:143-151, 1999.
	C7	Nemunaitis <i>et al.</i> , "Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer," <i>J. Clin. Oncol.</i> , 18:609-622, 2000.
	C8	Nielsen <i>et al.</i> , "Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer," <i>Clin. Cancer Research</i> , 4:835-846, 1998.
	C9	Pirollo <i>et al.</i> , "p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy," <i>Oncogene</i> , 14(14):1735-1746, 1997.
	C10	Roth <i>et al.</i> , "Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer," <i>Nat. Med.</i> , 2(9):985-991, 1996.

25747324.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.